Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1625 of 2529 entries
View as:

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT00537862 Org: User:
Start: 05/31/06 End: - Due: -

Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT01649427 Org: User:
Start: 10/17/12 End: 08/20/15 Due: 08/20/16

Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients

Phase: N/A Priority: Normal
NCT ID: NCT01582243 Org: User:
Start: 04/30/13 End: 09/30/15 Due: 09/30/16

Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00079937 Org: User:
Start: 04/30/04 End: 03/31/08 Due: 03/31/09

Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT02474069 Org: User:
Start: 02/08/15 End: 09/15/16 Due: 09/15/17

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

Phase: N/A Priority: Normal
NCT ID: NCT02226120 Org: User:
Start: 10/16/14 End: 12/28/17 Due: 12/28/18

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

Phase: N/A Priority: Normal
NCT ID: NCT01742286 Org: User:
Start: 08/28/13 End: 04/26/19 Due: 04/26/20

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Phase: N/A Priority: Normal
NCT ID: NCT06562192 Org: User:
Start: 10/15/24 End: 06/26/30 Due: 06/26/31

Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT03005288 Org: User:
Start: 02/01/17 End: 05/08/19 Due: 05/08/20

Verification Study of Ciclosporin for Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT00232076 Org: User:
Start: 05/31/04 End: - Due: -

Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma

Phase: N/A Priority: Normal
NCT ID: NCT01007149 Org: User:
Start: 09/30/09 End: 02/28/11 Due: 02/28/12

Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction Patients: a Real World Study in India

Phase: N/A Priority: Normal
NCT ID: NCT04735354 Org: User:
Start: 10/27/20 End: 06/01/22 Due: 06/01/23

This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

Phase: N/A Priority: Normal
NCT ID: NCT01250951 Org: User:
Start: 12/31/09 End: 09/30/11 Due: 09/30/12

Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT01348087 Org: User:
Start: 08/31/11 End: 09/30/14 Due: 09/30/15

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

Phase: N/A Priority: Normal
NCT ID: NCT03710564 Org: User:
Start: 10/30/18 End: 07/01/21 Due: 07/01/22

To Determine the Safety, Tolerability, Pharmacokinetics and Effect on Pain of a Single Intra-articular Administration of Canakinumab in Patients With Osteoarthritis in the Knee

Phase: N/A Priority: Normal
NCT ID: NCT01160822 Org: User:
Start: 04/30/10 End: 07/31/11 Due: 07/31/12

An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01009281 Org: User:
Start: 10/30/09 End: 08/19/10 Due: 08/19/11

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00941031 Org: User:
Start: 07/31/09 End: 12/31/10 Due: 12/31/11

Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

Phase: N/A Priority: Normal
NCT ID: NCT01624636 Org: User:
Start: 12/31/12 End: 05/31/13 Due: 05/31/14

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.

Phase: N/A Priority: Normal
NCT ID: NCT01080131 Org: User:
Start: 03/31/10 End: 10/31/11 Due: 10/31/12

Efficacy of QAX576 in Asthma

Phase: N/A Priority: Normal
NCT ID: NCT01130064 Org: User:
Start: 05/31/10 End: 04/30/12 Due: 04/30/13

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg

Phase: N/A Priority: Normal
NCT ID: NCT00751036 Org: User:
Start: 06/30/09 End: 08/31/12 Due: 08/31/13

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Phase: N/A Priority: Normal
NCT ID: NCT01283516 Org: User:
Start: 01/24/11 End: 05/03/16 Due: 05/03/17

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Phase: N/A Priority: Normal
NCT ID: NCT02955069 Org: User:
Start: 02/14/17 End: 05/13/20 Due: 05/13/21

Safety and Efficacy of BKM120 in Relapsed and Refractory NHL

Phase: N/A Priority: Normal
NCT ID: NCT01693614 Org: User:
Start: 02/28/13 End: 07/21/17 Due: 07/21/18